Clinical Trial Search

Primary: Revised Children's Manifest Anxiety Scale (RCMAS) — 24.88; 26.2; 17.91 units on a scale — p=<.001

Primary: Proportion of Participants Screened for Osteoporosis — 830; 33 participants

Primary: Acceptability of Enrollment and Randomization: Eligible But Declined Participation — 0; 0 Participants

Primary: Family Caregiver Well-Being Using GAD-7 Scale — 8.95 score on a scale

Primary: Evaluation of the Safety of MVA HIV-B at Week 2 in Arm 1 — 22 Participants

Primary: Number of Subjects With Optimal Intubating Conditions — 61; 47 Participants — p=0.036

Primary: Percentage of Participants Reported as Having an Improvement in Overall Skin Health as Evaluated by Dermatologist Grading — 29 Participants

Primary: Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) — -2.4; -1.3 score on a scale

Primary: Change in Score of Child Worker Job Stress Inventory — 25.1; 32.8 units on a scale

Primary: Safety Run-in Sub-study: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 8; 1 Participants

Primary: Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6 — 43.1; 46.9; 33.4; 4.0…

Primary: QT Interval — 623 ms

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) up to 24 Months — 0; 0; 0; 0 Participants

Primary: Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria In Solid Tumors RECIST 1.1 (Brand Name) or Death, Whichever Occurs…

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 5; 2; 6 Participants